| Literature DB >> 18058801 |
Hiromi Sato1, Hiromi Hagiwara, Hironobu Senba, Keiko Fukumoto, Yoji Nagashima, Hiroshi Yamasaki, Koichi Ueno, Tomohiro Yano.
Abstract
We have previously reported that connexin (Cx) 32 gene, a member of gap junctions, was specifically downregulated in human renal cell carcinoma (RCC) and it acts as a tumor suppressor against RCC. Because there is no standard therapy for advanced RCC, we investigated the anti-metastatic effect of Cx32 to seek a possibility of new RCC therapy. In this study, we used human metastatic RCC cell (Caki-1), and established Cx32-expressed cell clone (Caki-1T) or only mock-transfected cell clone (Caki-1W). For experimental production of metastases, the cells were injected into the lateral tail vein of SCID mice. Seventy days after inoculation, metastatic colonies were observed in Caki-1W inoculated group, though none of them were in Caki-1T inoculated group. The plasma VEGF concentration was significantly lower in Caki-1T group compared to Caki-1W group. To investigate where Cx32 effects on, we also tried in vitro analysis and found that the malignant phenotypes involving metastasis steps were significantly decreased in Caki-1T under hypoxia, a mimic condition of internal tumor environment. After hypoxia treatment, the protein level of HIF-2alpha, which plays main role for hypoxia adaptation, was observed to increase in Caki-1W, whereas no expression was observed in Caki-1T. We investigated the activation of Src, which is required for stabilization of HIF-2alpha, is suppressed in Caki-1T compared to Caki-1W. These results suggest that Cx32 inhibits hypoxia adaptation governed by HIF-2alpha, and this may help to reduce the metastasis of RCC cells. (c) 2007 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18058801 DOI: 10.1002/mc.20396
Source DB: PubMed Journal: Mol Carcinog ISSN: 0899-1987 Impact factor: 4.784